I would like to repeat flow cytometry on the blood of a patient with HTLV-1 T-Cell Leukemia/Lymphoma (CD 4+, CD 25+), to assess CD52 status. The patient is currently being treated with Campath - 1H, a humanized monoclonal antibody that is reactive with CD52 (his disease was found to be CD52+ in the past). The patient no longer seems to be responding to Campath therapy,and his disease now appears to be CD 52- by flow. I am concerned that the Campath - 1 H (most recent dose yesterday) could be masking any CD52 present on the patient's malignant cells. Does anybody know of literature addressing this issue, or otherwise have suggestions. Thank you very much for any assistance that you can provide. Roger Klein, M.D.
This archive was generated by hypermail 2b29 : Sun Jan 05 2003 - 19:01:38 EST